Red-Light Phototherapy for Nasal Congestion: Limited Evidence, Not Guideline-Recommended
Red-light phototherapy devices like Cleriva's NovaFlow are not mentioned in current clinical practice guidelines for managing nasal congestion, and while emerging research shows some promise for allergic rhinitis symptoms, the evidence remains insufficient to recommend this as standard therapy.
Guideline-Based Standard of Care
The AAO-HNS clinical practice guidelines for allergic rhinitis 1 and sinusitis 2, 3 do not include phototherapy or red-light devices as recommended treatment options. Instead, established therapies include:
- Intranasal corticosteroids (first-line for allergic rhinitis)
- Topical decongestants (oxymetazoline for severe obstruction, limited to 3-5 days to avoid rebound congestion) 1, 2
- Oral antihistamine-decongestant combinations (when nasal sprays are not tolerated) 1
- Nasal saline irrigation (adjunctive therapy for symptom relief) 2
Research Evidence on Red-Light Therapy
Most Recent High-Quality Evidence
The most recent randomized controlled trial (2025) examining photobiomodulation therapy (PBMT) for allergic rhinitis showed 4:
- Significant improvement in peak nasal inspiratory flow (p < 0.001)
- Significant improvement in Nasal Obstruction Symptom Evaluation scale (p = 0.048)
- Significant improvement in Rhinitis Control Assessment Test (p = 0.035)
- Protocol: 6 J red/infrared light intranasally + 1 J infrared externally, twice weekly for 8 sessions
Supporting Studies
A 2021 study 5 found that adding rhinophototherapy (UVA, UVB, visible light) to intranasal beclomethasone improved nasal patency objectively (p = 0.004 for inspiratory nasal resistance) and subjectively compared to medication alone.
Contradictory Evidence
However, a 2018 study 6 showed that red-light rhinophototherapy did not objectively improve nasal patency despite subjective symptom improvement that was short-lived (worsened again after 2 days).
A 2011 systematic review 7 concluded that the strength of recommending intranasal phototherapy is currently weak due to variable study quality, lack of objective airflow improvement, and equivocal effects on inflammatory markers.
Critical Limitations and Safety Concerns
Key Caveats:
- No long-term safety data for repeated intranasal light exposure
- DNA damage potential documented, though carcinogenesis risk unclear 7
- Recent safety concerns with red-light devices: A 2026 study 8 found some laser-based red-light devices reached ANSI safety limits within exposure times below recommended treatment duration, leading to regulatory reclassification in China
- Lack of standardization across devices (wavelengths range from 660 nm red light to UVA/UVB combinations)
- Short-lived effects in some studies 6
Clinical Recommendation
For patients with nasal congestion, prioritize guideline-recommended therapies first 1, 2:
- Allergic rhinitis: Start with intranasal corticosteroids
- Severe obstruction: Add topical oxymetazoline for ≤3 days
- Inadequate response: Consider combination therapy or immunotherapy referral
Red-light phototherapy may be considered as an experimental adjunct for patients with allergic rhinitis who cannot tolerate conventional medications 4, but this should be:
- Discussed as off-guideline therapy with uncertain long-term safety
- Used only with devices that have undergone independent safety validation
- Not used as monotherapy or first-line treatment
- Monitored closely for efficacy and adverse effects
The absence of this modality from established guidelines, combined with safety concerns and inconsistent objective outcomes, means it cannot be recommended over proven therapies at this time.